However, in a mouse bladder cancer model with FGFR3-activating mutations, inhibition of FGFR rescinded the ubiquitination and degradation of PD-L1 by NEDD4 and significantly reduced the ratio of Ki67, TNF-α, GZMB and perforin positivity released from activated CD8+ T-cells, which severely inhibits the tumor-killing effect of CD8+ T-cells [25]. The gene discussed is CD8A; the disease is urinary bladder cancer.